Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
14 November 2012

Bionomics Limited (ASX:BNO) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all resolutions considered before the Annual General Meeting today.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 12 October 2012.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

			Proxy Votes			
Resolution Number	Resolutions	Result	For	Against	Open	Abstain
1	Adoption of Remuneration Report	Passed on a show of hands	54,829,676	1,090,720	22,294,658	37,673,117
2	Re-election of Non-Executive Director – Mr Trevor Tappenden	Passed on a show of hands	96,472,430	479,692	22,305,658	451,601
3	Election of Non-Executive Director – Dr Jonathan Lim	Passed on a show of hands	96,818,968	124,600	22,425,658	340,155
4	Election of Non-Executive Director – Mr Graeme Kaufman	Passed on a show of hands	96,744,092	184,000	22,337,388	443,901
5	Increase in Aggregate Remuneration for Non-Executive Directors	Passed on a show of hands	49,374,929	44,106,224	20,103,630	117,070
6	Approval of Proposed Issued of Share Options to Dr Deborah Rathjen: For the year ended 30 June 2012	Passed on a show of hands	50,072,872	43,046,655	20,166,557	189,196
7	Approval of Proposed Issued of Share Options to Dr Jonathan Lim	Passed on a show of hands	50,412,477	42,869,756	20,166,557	26,490
8	Approval of Proposed Issued of Share Options to Mr Graeme Kaufman	Passed on a show of hands	50,132,241	43,040,886	20,166,557	135,596
9	Ratification and approval of previous issue and allotment of shares	Passed on a show of hands	55,351,349	38,106,208	22,603,009	518,407

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

Ms Melanie Young
CFO & Company Secretary
+618 8354 6107 / 0414 264 547
myoung@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis.

BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.

For more information about Bionomics, visit www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143(BNC210), our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deal with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors' products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.